New board of directors appointed in Targinta AB

The appointment of a new board of directors in Targinta is part of the preparations for the previously communicated objective that Targinta is to become an independent and self-financed company.

Jeffrey Abbey, born 1962, has more than 20 years experience from the biopharmaceutical industry with a significant part being devoted to the development of innovative cancer therapies, notably as CEO at Argos Therapeutics, a clinical immuno-oncology company that he led to a public listing at Nasdaq US. Prior to that Jeffrey was CBO at Argos.
Other current undertakings: COO and CBO at ImmunOs Therapeutics.
Education: MBA and a JD at University of Virginia and a BS i mathematics and economy at Brown University.

Karin Wingstrand, born 1957, is an advisor with the pharmaceutical industry. Previous positions includes being global head of clinical science at AstraZeneca R&D, as well as being global head of pharmaceutical and analytical science at AstraZeneca R&D. She has also been a member of the board of directors of Swecure AB, Adenovir Pharma AB and Aqilion AB and chair of the board of directors of Mevia AB.
Other current undertakings: Member of the board of T-bolaget Aktiebolag, Xbrane Biopharma AB, Histolab Products AB, Winkon Holding AB, Integrum AB, and Xintela AB.
Education: Pharmacist at Uppsala universitet.

Maarten de Château, born 1963, has broad experience from drug development, working as life science research analyst at Aragon Fondkommission and Swedbank Markets, and as medical advisor at Sanofi-Aventis, as well as medical director at Biovitrum/Sobi. He was the founder and CEO of Cormorant Pharmaceuticals and Buzzard Pharmaceuticals, and has been a member of the board of directors of OxThera AB, Addbio AB, Gesynta Pharma AB, and Evident Life Försäkring AB.
Other current undertakings: Chair of the board of Atrogi AB, member of the board of Beactica Therapeutics AB, Cavis Technologies AB, Buzzard Pharmaceuticals AB, MetaCurUm Biotech AB and Amarna Holding BV. CEO at Sixera Pharma AB, Buzzard Pharmaceuticals AB and MetaCurUm Biotech AB.
Education: M.D. and PhD at Lunds universitet.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: [email protected]
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela
Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells (XSTEM) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [email protected].

About Targinta
Targinta is a preclinical stage oncology biotech company, developing first-in-class therapeutic antibodies for treatment of aggressive cancers such as glioblastoma and triple-negative breast cancer. The pipeline includes TARG10, which is a humanized function-blocking antibody in preclinical development targeting intergrin α10β1, a tumor-associated antigen protected by Targinta's IP portfolio. In addition, Targinta's pipeline includes a preclinical program to develop an antibody-drug conjugate (ADC) targeting intergrinα10β1. Targinta is a wholly owned subsidiary of Xintela AB (publ) and is headquartered in Lund, Sweden. For more information, please visit www.targinta.se.